Vitamin D exposure, or lack of it, has long been thought to influence the risk of developing multiple sclerosis (MS) because the disease is diagnosed more often in people in northern countries.
An experimental antibody therapy for multiple sclerosis can cut symptom flare-ups by half, versus a standard treatment, a new clinical trial has found.
For people with multiple sclerosis, certain factors early in their disease may determine their quality of life in the years to come, a new study suggests.
